Xencor to co-develop IL-15 therapies with Genentech

Xencor Inc. (NASDAQ:XNCR) will receive $120 million up front in a deal to co-develop its IL-15 cytokine therapeutics, including XmAb24306, with Genentech Inc.

The partners will evaluate combinations of

Read the full 280 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE